JDL(SH:688057) 智通财经网·2025-12-19 08:20Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Yunnan Jici Medical Technology Co., Ltd. [1] Group 1 - The company intends to invest 280 million yuan of its own funds to acquire a 34% stake in Yunnan Jici Medical Technology Co., Ltd. [1] - Yunnan Jici Medical has unique advantages in the field of cell dedifferentiation and rejuvenation research, having established a technology system that induces skin fibroblasts into specific functional cells without going through the induced pluripotent stem cell (iPSC) stage [1] - The company has developed a series of autologous cell preparations or their derivatives, including first-generation induced mesenchymal stem cells (rFib), second-generation induced mesenchymal stem cells (cFib), induced osteoblasts (iOB), induced chondrocytes (iCH), induced neurons (iNC), induced endothelial cells (iEC), and induced vascular smooth muscle cells (iVSMC) [1] Group 2 - Yunnan Jici Medical has pioneered a new field of autologous cell therapy and tissue engineering research for refractory diseases, particularly refractory geriatric diseases, based on its original series of stem cell patent technologies [2] - The company has obtained 20 invention patents in countries including China, the United States, Japan, Canada, Australia, and Malaysia [2]